Basic Information
| LncRNA/CircRNA Name | FBXL19-AS1 |
| Synonyms | NA |
| Region | GRCh38_16:30919319-30923269 |
| Ensemble | ENSG00000260852 |
| Refseq | NR_024348 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot |
| Sample | NSCLC cell lines (A549, H1299, H520, SPCA1, and H358) and normal lung epithelial cells (16HBE), carcinoma and para-carcinoma tissues |
| Expression Pattern | up-regulated |
| Function Description | The results of qRT-PCR showed that the expression of lncRNA FBXL19-AS1 in NSCLC tissues and cells was up-regulated. According to the results of the colony formation assay, the proliferative capacity of NSCLC cells was decreased after the interference with lncRNA FBXL19-AS1 expression. In flow cytometry, it was indicated that the cell cycle was arrested at the G0/G1 phase in the experimental group compared with that in the control group. The transwell assay results showed that the migratory and invasive abilities of NSCLC cells were weakened after the interference with lncRNA FBXL19-AS1 expression. The results of the Western blotting assay revealed that the expressions of EMT-related molecular markers (E-cadherin, N-cadherin, etc.) were changed. |
| Pubmed ID | 31210311 |
| Year | 2019 |
| Title | LncRNA FBXL19-AS1 promotes proliferation and metastasis via regulating epithelial-mesenchymal transition in non small cell lung cancer |
External Links
| Links for FBXL19-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |